Clinical Trials Browser

Phase 2/3 × Hyperaldosteronism × Clear all

NCT06100367 2025-12-02

11C-Metomidate PET/CT for Endocrine Hypertension and Characterisation of Adrenal Tumours

Phase 2/3 Active not recruiting

Adrenal Gland Neoplasms, Hyperaldosteronism, Neoplasm Metastasis